S874
Clinical - Mixed sites & palliation
ESTRO 2026
Our retrospective group is to our knowledge the largest study of palliative radiotherapy in patients aged 90 and older with advanced head and neck cancers. Palliative RT appeared to be safe and effective – no grade 3-4 adverse events were observed and 47% of patients did not suffer progression. The role of G-8 score and impact of palliative radiotherapy on quality of life needs to be farther evaluated in this subgroup of elderly patients. References: 1. Bellera CA, Rainfray M, Mathoulin-Pelissier S, et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012;23(8):2166–72.2. Masahiro Takahashi, Masanobu Takahashi, Keigo Komine et al. 2017; The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. Keywords: geriatric, nonagenarian, G8 screening tool
cancer were identified: 16 (56%) female and 11 (44%) male. Median age was 92 (range 90-100). Median OS was 5,4 months (range 0-73) and estimated 24 months OS was 30.3 %, Figure 1. ECOG performance status at the beginning of RT yield 1, 2 and 3 in 20%, 56% and 24%, respectively, Figure 2. One patient received adjuvant radiotherapy and therefore was withdraw from farther analysis of palliative RT. All patients received prescribed dose (20 Gy in 5 fractions, n=10; 8 Gy in 1 fraction, n=7; 30 Gy in 5 or 10 fractions, n=5; 16 Gy in 2 fractions, n=2). Eight patients were hospitalised (33%), other received ambulant treatment. G-8 score was prospectively assessed in 11 patients and yield in average 9 (rage 7-11). All patients, but two, had loco(regionally)advanced T3/T4 and/or N3 tumour. Primary tumour localisation encompassed skin (n=15), oral cavity (n=4), larynx (n=2), salivary glands (n=2) and hypopharynx (n=1). 67% were squamous cell carcinomas, 8% basal cell carcinomas, 4% ACC, 4% DLBCL lymphoma, 4% Merkel Cell Carcinoma and others. No grade 3-4 adverse events were observed. Treatment response could be evaluated in 19 patients (79%). Ten (53%) of these patients experienced progression. Median TTP yield 7.1 month (range 0-9). Seven patients could receive reirradiation while progression was diagnosed. The average survival after reRT yield 9.8 month (range 1-23).
Digital Poster Highlight 1571
Overcoming palliation by single ultra-high dose partial irradiation of complex bulky tumors allied with immune-/targeted therapy: first-in-human data. Slavisa Tubin, Mohamed Mamoun Morad, Johanna Salinger, Dominik Frey, Christoph Resl, Carmen Döller, Ratna Shree Dhungana, Petra Georg Radiation Oncology, Universitätsklinikum Krems, Krems an der Donau, Austria Purpose/Objective: This report shows the results of the first clinical implementation of an innovative treatment concept consisting of combined ultra-high-dose partial tumor irradiation (PTI) and immuno-/targeted therapy, used as a last attempt to convert an already declared palliative conventionally-untreatable disease into a potentially curative one. Patients who were treated with this approach according to the tumor boards had no further therapeutic options left after all available standard of care treatments failed, or were not feasible due to tumor size-volume, location or extensive-full contact with surrounding organs. Despite a very short life expectancy and poor KPS,
Conclusion:
Made with FlippingBook - Share PDF online